European health authorities are conducting fewer good manufacturing practice inspections at facilities regulated under the EU’s centralized marketing procedure thanks to a recent US/EU mutual recognition agreement on drug GMP inspections, according to the European Medicines Agency’s 2017 annual report.
The report, issued on May 2, said that after an increase every year, the number of GMP inspections dropped...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?